Part C: Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have a diagnostic quality computed tomography (CT) scan or magnetic resonance imaging (MRI), performed within  days prior to registration, which demonstrates measurable disease, as defined in RECIST v. .; all disease must be assessed and documented on the S Baseline Tumor Assessment Form
In the expansion cohort: subjects must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version .; bone lesions are not considered measurable by definition
At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on RECIST version .
At least  measurable lesion as defined by RECIST . on imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI])
All patients must have measurable disease documented by computed tomography (CT), magnetic resonance imaging (MRI), or nonmeasurable disease documented by physical exam within  days prior to registration
Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST v..
Patients must have measurable or non-measurable (evaluable) disease recurrence; recurrence must be documented by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Patients must have measurable disease according to RECIST criteria on anatomic imaging studies (computed tomography [CT] scan or magnetic resonance imaging [MRI])
Measurable disease on imaging studies (magnetic resonance imaging [MRI], computed tomography [CT], PET-CT or physical exam)
Subject has at least  measurable lesion per RECIST v. criteria by computed tomography (CT) scan or magnetic resonance image (MRI).
Patient must have recent imaging (computed tomography [CT] or magnetic resonance imaging [MRI], as appropriate) within  weeks of trial enrollment, demonstrating measurable disease as defined by RECIST ..
Evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable FDG-avid lesions on PET)
Measurable disease, even after resection of applicable lesion for TIL harvest; defined as >=  lesion that is >=  mm in one dimension by computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers on clinical exam
Measurable disease by RECIST v. criteria (tumor >=  cm in longest diameter on axial image on computed tomography (CT) or magnetic resonance imaging (MRI) and/or lymph node(s) >= . cm in short axis on CT or magnetic resonance imaging [MRI]) on baseline imaging
Patients must have at least one lesion that is not within a previously radiated field and that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scans per RECIST version .; bone lesions are not considered measurable
Active disease measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have measurable disease according to the standard RECIST version .\r\n* NOTE: computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess the measurable disease must have been completed with  days prior to the study drug initiation
At least  measurable lesion > . cm in at least  dimension by computed tomography or magnetic resonance imaging.
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] suitable for assessment as per RECIST .. The baseline scan must be obtained within  days prior to the first dose of olaparib.
Patients must have measurable disease, by computed tomography (CT) or magnetic resonance imaging (MRI) per modified RECIST criteria for mesothelioma; radiographic tumor assessment must be performed within  days prior to the first treatment
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST .
Must have evaluable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan, according to RECIST . (subjects with measurable disease per RECIST . or radiographically visible and evaluable disease). Subjects with only ascites or pleural effusion are excluded.
Participants must have evaluable or measurable disease based on RECIST . using computed tomography (CT)/magnetic resonance imaging (MRI).
Measurable disease by computed tomography (CT) or similar (e.g. magnetic resonance imaging [MRI]) criteria (> . cm)
Disease in the liver must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI).
Measurable disease by computed tomography or magnetic resonance imaging based on RECIST . as determined by site radiology.
Patients must have measurable disease per RECIST . assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)
At least  radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST . criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
Must have measurable disease per RECIST . as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI). a. Lesion/s deemed accessible to biopsy for both before and on-treatment biopsies.
Measurable or evaluable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version (v).
Must have measurable disease by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients will only be eligible for this trial if they have disease with tumor measurable on the computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v. criteria.
Measurable Diffuse Large B-Cell Lymphoma disease by Computed Tomography (CT) / Magnetic Resonance Imagining (MRI) scans
Patients must have measurable disease in the pancreas; computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within  days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form
Measurable disease determined by computed tomography (CT) or magnetic resonance imaging (MRI)
Presence of at least  measurable lesion by computed tomography or magnetic resonance imaging per RECIST v..
Measurable disease defined per RECIST v. ., or bone-only disease must have a lytic or mixed lytic blastic lesion that can be accurately assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Individuals with bone-only disease and blastic-only metastases are not eligible
Has progression and measurable disease in the brain by magnetic resonance imaging (MRI) or computed tomography (CT)
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Bi-dimensionally measurable disease on cross sectional imaging by X-ray Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST . criteria; radiographic tumor assessment performed within  days of study inclusion
Metastatic diseases measurable or evaluable on a computed tomography (CT) or magnetic resonance imaging (MRI) scan according to RECIST . criteria; locally recurrent disease that is not amenable to potentially curative surgery or radiation therapy is also allowed; lesions must be >=  mm in size; recurrent or metastatic disease within a prior radiation field is acceptable as long as the disease has progressed in the radiation field by RECIST criteria
Subject has measurable disease by radiographic techniques (computerized tomography [CT] or magnetic resonance imaging [MRI]);
Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST . criteria
one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least .  . cm, Exception: For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.
Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST . criteria
Has progression of brain cancer and measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan; for leptomeningeal metastases, positive cytology is acceptable if imaging is not measurable
At least  lesion (measurable by RECIST v.) that can be accurately assessed at baseline by computed tomography (CT)/magnetic resonance imaging (MRI) and is suitable for repeated assessment;
Subjects must have evidence of measurable disease per RECIST version . by radiographic techniques or magnetic resonance imaging
Patients must have at least  evaluable lesion. Lesions must be evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients with non-quantifiable monoclonal proteins are eligible provided they meet other criteria for multiple myeloma and they have evaluable or measurable disease by other (radiographic, magnetic resonance imaging [MRI], computed tomography [CT], lytic measurable lesion on x-ray,) means
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST . criteria\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
Patients with metastatic disease, target lesion must be measurable using computed tomography (CT) or magnetic resonance imaging (MRI)
Must have disease measurable by RECIST . criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v..
Has measurable disease (or evaluable if not in MTD expansion cohort) via computed tomography (CT) or magnetic resonance imaging (MRI) scans with or without non-measurable tumors (a lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of that lesion prior to enrollment)
Subjects must have at least one lesion that is not within a previously radiated field that is evaluable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version .; if the subjects only evaluable disease is within a previously radiated field, it must have demonstrated progression since the time of radiation
Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version .
Subjects must have measurable disease by computed tomography (CT) scans or magnetic resonance imaging (MRI) per RECIST . criteria; radiographic tumor assessment must be performed within  days prior to first dose of study drug
Patients with at least  measurable tumor lesion as assessed by Computed Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) according to RECIST ..
Patients must have measurable disease, documented by clinical, radiographic or histologic criteria; disease must be bi-dimensionally measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI) or plain X-ray and is suitable for repeated assessment
